Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | November 28, 2018 | November 30, 2018 |
| MAXCYTE, INC.MXCT · Entity 6608 | Director | June 17, 2026 | June 22, 2026 |
| NOVAVAX INCNVAX · Entity 4632 | Director · President and CEO | December 14, 2022 | December 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date November 28, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,333 |
Reported balance
After 2018-11-28 transaction · row 1
1 source rowRow 1 · 2018-11-28 · Exercise / conversion · Acquired 8,333 · Balance 48,333 |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2018-12-22 | Direct | 0 |
Reported balance
After 2018-11-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-28 · Exercise / conversion · Disposed 8,333 · Balance 0 |
MAXCYTE, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 428,749 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 428,749 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16 | Direct | 49,579 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579 F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
NOVAVAX INC
Report date December 14, 2022 · Filed December 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,812 |
Reported balance
After 2022-12-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-12-14 · Exercise / conversion · Acquired 6,966 · Balance 38,812 F1: The shares were received by the Reporting Person in connection with vesting of restricted stock units ("RSUs"). F2: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Common StockSEC Table I · non-derivative | Direct | 36,492 |
Reported balance
After 2022-12-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-12-14 · Tax withholding · Disposed 2,320 · Balance 36,492 F3: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs. F4: The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,967 |
Reported balance
After 2022-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-14 · Exercise / conversion · Disposed 6,966 · Balance 6,967 F2: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F5: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were received by the Reporting Person in connection with vesting of restricted stock units ("RSUs").
F2: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F3: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs.
F4: The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022.
F5: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 6,984 | $214.97 | $1,501,337.21 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 10 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,824 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.63 to $215.55, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 12,917 | $214.13 | $2,765,878.46 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 9 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,808 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.61 to $214.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 12,703 | $213.07 | $2,706,640.91 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 8 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,725 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.60 to $213.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 6,419 | $212.15 | $1,361,808.18 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 7 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,428 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.58 to $212.57, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 4,117 | $211.07 | $868,966.54 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 6 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,847 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.57 to $211.47, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 6,105 | $210.02 | $1,282,189.80 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 5 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,964 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.57 to $210.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,046 | $209.20 | $428,028.72 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 4 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,069 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.56 to $209.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 17,560 | $121.00 | $2,124,760.00 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 3 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 19,879 | $36.60 | $727,571.40 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 2 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 15,181 | $25.60 | $388,633.60 |
DisclosureSEC source: 0001209191-21-045558 · doc4.xml · nonDerivative · entry 1 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 20,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063827 · doc4.xml · derivative · entry 2 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 41,700 | $0.00 Strike: $129.70 | $0.00 |
DisclosureSEC source: 0001209191-20-063827 · doc4.xml · derivative · entry 1 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,700 Underlying: Common Stock · 41,700 shares Expires 2030-12-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 14, 2020 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to buy) · Derivative | 9,818 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · derivative · entry 10 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,182 Underlying: Common Stock · 9,818 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to buy) · Derivative | 42,499 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · derivative · entry 9 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,499 shares Expires 2021-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the June 22, 2011 grant date. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 4,909 | $93.56 | $459,292.42 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 8 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,495 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.21 to $93.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 17,503 | $92.97 | $1,627,290.67 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 7 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,404 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.21 to $93.205, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 4,598 | $90.61 | $416,637.65 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 6 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,907 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.99 to $90.90, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 11,234 | $89.26 | $1,002,708.64 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 5 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,505 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.97 to $89.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 8,306 | $88.36 | $733,918.16 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 4 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,739 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.95 to $88.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,766 | $87.20 | $502,819.42 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 3 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,045 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.95 to $87.92, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 9,818 | $25.60 | $251,340.80 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 2 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 23:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 42,499 | $39.80 | $1,691,460.20 |
DisclosureSEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 1 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2 | $108.57 | $217.13 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 11 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,494 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $115.65 | $11,565.00 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 10 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,496 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $115.43 | $11,543.00 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 9 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,596 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 800 | $114.73 | $91,784.00 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 8 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,696 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.40 to $115.11, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 700 | $114.20 | $79,940.00 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 7 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,496 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.29 to $114.20, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 800 | $112.65 | $90,118.00 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 6 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,196 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.25 to $113.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 900 | $111.41 | $100,270.98 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 5 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,996 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.10 to $111.85, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,676 | $110.54 | $185,269.73 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 4 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,896 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,500 | $109.54 | $164,304.00 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 3 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,572 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.05 to $110.01, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,138 | $108.56 | $557,796.69 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 2 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,072 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.02 to $109.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:39 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 517 | $107.56 | $55,608.99 |
DisclosureSEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 1 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,210 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.90, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,000 | $109.25 | $109,251.00 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 19 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,727 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.99 to $109.45, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,112 | $108.40 | $120,543.58 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 18 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,727 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.92 to $108.77, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,000 | $107.25 | $107,248.00 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 17 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,839 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.86 to $107.68, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,000 | $106.22 | $106,224.00 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 16 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,839 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.69 to $106.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Appreciation Right · Derivative | 25,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · derivative · entry 21 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 12,233 shares of common stock upon the net exercise of 25,000 stock appreciation rights. The reporting person forfeited 1,338 shares of common stock underlying the stock appreciation rights representing the base value and 11,429 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on September 28, 2020 of $111.18. F19 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant vested on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · derivative · entry 20 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the September 26, 2019 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 551.38 | $117.07 | $64,547.63 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 15 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,839 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.61 to $117.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 950.63 | $116.08 | $110,346.28 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 14 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,390 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.61 to $116.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,002.51 | $115.23 | $115,520.83 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 13 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,341 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.61 to $115.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 401 | $113.81 | $45,639.13 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 12 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,343 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.61 to $114.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 726.82 | $113.02 | $82,148.10 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 11 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,744 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.61 to $113.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 215.54 | $111.92 | $24,124.01 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 10 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,471 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.61 to $112.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,343.11 | $110.97 | $260,023.82 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 9 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,687 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.61 to $111.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 8,132.83 | $109.98 | $894,439.70 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 8 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,030 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.61 to $110.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 6,661.4 | $109.07 | $726,546.24 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 7 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,163 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.61 to $109.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,739.1 | $108.20 | $404,560.15 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 6 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,824 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.61 to $108.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:27 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 275.69 | $107.22 | $29,559.67 |
DisclosureSEC source: 0001209191-20-052524 · doc4.xml · nonDerivative · entry 5 Erck Stanley C · CIK 0001342826 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,563 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.61 to $107.60, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.